PROSTATYPE GENOMICS AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0416 SEK | +7.22% |
|
+1.96% | -56.21% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Capitalization 1 | 188.6 | 134.9 | 48.46 |
| Enterprise Value (EV) 1 | 174.2 | 115.8 | 37.84 |
| P/E ratio | - | -8.09 x | -1.38 x |
| Yield | - | - | - |
| Capitalization / Revenue | 62.7 x | 53.8 x | 71 x |
| EV / Revenue | 57.9 x | 46.2 x | 55.4 x |
| EV / EBITDA | -14.3 x | -7.49 x | -1.32 x |
| EV / FCF | - | -9,108,579 x | -2,252,843 x |
| FCF Yield | - | -0% | -0% |
| Price to Book | 6.67 x | 3.76 x | 1.85 x |
| Nbr of stocks (in thousands) | 13,187 | 15,089 | 22,859 |
| Reference price 2 | 14.30 | 8.940 | 2.120 |
| Announcement Date | 5/17/21 | 5/5/22 | 5/4/23 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 4.996 | 4.823 | 3.308 | 3.008 | 2.51 | 0.6828 |
| EBITDA 1 | -4.519 | -8.97 | -7.708 | -12.15 | -15.46 | -28.64 |
| EBIT 1 | -4.625 | -9.164 | -7.862 | -12.25 | -15.55 | -28.69 |
| Operating Margin | -92.59% | -190.01% | -237.63% | -407.31% | -619.54% | -4,201.87% |
| Earnings before Tax (EBT) 1 | -4.747 | -9.318 | -8.546 | -13.69 | -15.63 | -29.09 |
| Net income 1 | -4.747 | -9.318 | -8.546 | -13.69 | -15.63 | -29.09 |
| Net margin | -95.02% | -193.2% | -258.31% | -455.05% | -622.79% | -4,259.9% |
| EPS | - | - | - | - | -1.106 | -1.533 |
| Free Cash Flow | - | - | - | - | -12.72 | -16.8 |
| FCF margin | - | - | - | - | -506.71% | -2,459.96% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/17/17 | 12/17/18 | 12/6/19 | 5/17/21 | 5/5/22 | 5/4/23 |
1SEK in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 |
|---|---|
| Net sales 1 | 0.0557 |
| EBITDA 1 | -9.587 |
| EBIT 1 | -10.06 |
| Operating Margin | -18,061.64% |
| Earnings before Tax (EBT) | - |
| Net income | - |
| Net margin | - |
| EPS 2 | -0.0800 |
| Dividend per Share | - |
| Announcement Date | 8/17/23 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 1.37 | 4.16 | - | - | - |
| Net Cash position 1 | 8.39 | - | - | 14.4 | 19.1 | 10.6 |
| Leverage (Debt/EBITDA) | - | -0.1525 x | -0.5397 x | - | - | - |
| Free Cash Flow | - | - | - | - | -12.7 | -16.8 |
| ROE (net income / shareholders' equity) | -69.8% | -88.1% | -116% | - | -48.7% | -93.7% |
| ROA (Net income/ Total Assets) | -24.2% | -29.1% | -26.4% | - | -26.3% | -50.4% |
| Assets 1 | 19.59 | 32.07 | 32.42 | - | 59.4 | 57.71 |
| Book Value Per Share | - | - | - | 2.150 | 2.380 | 1.140 |
| Cash Flow per Share | - | - | - | 1.200 | 0.6500 | 0.2100 |
| Capex | - | - | - | 0.03 | - | - |
| Capex / Sales | - | - | - | 0.87% | - | - |
| Announcement Date | 11/17/17 | 12/17/18 | 12/6/19 | 5/17/21 | 5/5/22 | 5/4/23 |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -56.21% | 3.52M | |
| -16.55% | 8.43B | |
| +39.29% | 3.62B | |
| -38.71% | 2.61B | |
| -8.23% | 2.48B | |
| -7.96% | 2.34B | |
| -14.34% | 1.94B | |
| -19.24% | 1.56B | |
| -38.35% | 1.26B | |
| +6.91% | 1.1B |
- Stock Market
- Equities
- PROGEN Stock
- Financials Prostatype Genomics AB
